Methods of treating obesity, diabetes, and liver dysfunction
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsSandra KLEINER, Jason MASTAITIS, Mark W. SLEEMAN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for improving glucose control, increasing lean body mass, reducing fat mass, treating obesity, diabetes, and/or treating liver dysfunction in a subject. More specifically, the disclosure relates to compositions comprising a GDF-8 inhibitor and a GLP-1 agonist and uses thereof, as well as to compositions comprising a GDF-8 inhibitor, an Activin A inhibitor, and a GLP-1 agonist and uses thereof.
Claims35
A composition comprising a Growth and Differentiation Factor-8 (GDF-8) inhibitor and a Glucagon-like peptide-1 (GLP-1) agonist.
A composition comprising a Growth and Differentiation Factor-8 (GDF-8) inhibitor, an Activin A inhibitor, and a Glucagon-like peptide-1 (GLP-1) agonist.
A method for improving glucose control, increasing lean body mass, reducing fat mass, treating obesity, treating diabetes, and/or treating liver issues associated with increased fat mass, obesity, and/or diabetes in a subject, comprising administering a GDF8 inhibitor and a GLP-1 agonist to the subject.
A method for improving glucose control, increasing lean body mass, reducing fat mass, treating obesity, treating diabetes, and/or treating liver issues associated with increased fat mass, obesity, and/or diabetes in a subject, comprising administering a GDF8 inhibitor, an Activin A inhibitor, and a GLP-1 agonist to the subject.
Dependencies are inferred from the claim text.